• Announced the signing of a supplier agreement between Medline Industries and Amerinet for Bovie branded electrosurgical generators and accessories. The supply agreement names Bovie Medical through Medline Industries and one other manufacturer as suppliers of electrosurgical equipment and accessories.
• Nine month revenues were $20,420,272 versus $20,958,672 reported during the first nine months of 2008. Net income totaled $568,136 or $.03 per diluted share compared to net income of $1,793,021 or $.10 per diluted share in the comparable period in 2008, during which the Company had realized a gain of $1,495,634 from the acquisition of intellectual property in a non-monetary exchange from a contract settlement.
• August 2009 received FDA 510(k) clearance to market its J-Plasma ICON GS electrosurgical generator and handpiece.
• October 2009 received FDA 510(k) clearance to market laparoscopic SEER for solid organ resection.
• Submitted 510(k) applications seeking pre-market clearance for:
  • BOSS soft tissue coagulation device.
  • Seal-N-Cut™ vessel sealing line of hybrid monopolar and bipolar forceps.
  • ICON VS electrosurgical generator designed to work with the Seal-N-Cut™ vessel sealing .
  • ICON VS electrosurgical generator designed to work with the Seal-N-Cut™ vessel sealing instruments.

The Company’s products compete primarily in the multi-billion dollar market for electrosurgical generators and single-use specialty medical products. Industry demand for electrosurgical medical products is being favorably impacted by several trends including: the aging population, increased emphasis on less invasive surgical procedures, higher level of outpatient care, continuing pressure to improve productivity and reduce costs; and the heightened awareness for reducing the transmission of infectious diseases.

Polarian Seal-N-Cut™ Vessel Sealing Instruments - Approximate worldwide market $1 billion
The patent pending Polarian line of forceps allows for monopolar and bipolar energy combined with intelligent feedback from an electrosurgical generator. The Polarian handle will accommodate a wide array of possible applications in either monopolar or bipolar surgeries serving the endoscopic needs. The Endoscopy market is the fastest growing market in electrosurgery. The Polarian line of instruments is subject to FDA 510k clearance to market.

SEER/BOSS Tissue Resection Devices – Approximate worldwide market $500 million
The patent pending technology uses conductive sintered steel as an electrode for radio frequency (RF) cutting and coagulation, intended to lower blood loss, quicken procedure times and provide cost savings for hospitals.  Potential fields of therapy for the technology include liver, pancreatic and kidney tumor therapies along with orthopedic and blood vessel sealing.  The process involves delivery of RF current and sterile saline for resection, hemostatic sealing and coagulation in open and laparoscopic surgery. The BOSS is subject to FDA 510(k) clearance to market.

J-Plasma ICON GS electrosurgical generator - Approximate total worldwide market exceeds $2 billion
The technology utilizes a gas ionization process producing a stable thin beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon great precision, minimal invasiveness and an absence of conductive currents during surgery. Potential markets include gynecology, urology, dermatology, plastic surgery, neurology, gastroenterology, and veterinary medicine. Bovie anticipates directing its resources to each individual niche as best suited to the Company's overall business plan.

Modular Ergonomic Instruments (MEG Line) - Approximate worldwide market $200 million arthroscopic/ $300 million laparoscopic
The patent pending advanced modular forceps come with light metallic grips, transparent ratchet and ergonomic design, which is expected to reduce surgeon fatigue and improve tactile feel. The MEG family of forceps combined with Bovie’s electrosurgical generators offers users cost savings through simplified inventory management.

ICON GI - Approximate worldwide market for GI/Argon generators and accessories $150 million
The ICON GI was designed in collaboration with GI physicians and nurses and offers many new features including digital output, a touch screen interface, physician preference database, neutral electrode monitoring, and common sense messages. The ICON platform provides the basis to develop customized generators for other specialties.

Standard Electrosurgical Generators & accessories - Approximate worldwide $80 million
Standard electrosurgical generators range in power from 30-300 watts and are used in physician offices, surgery centers and hospitals. Bovie holds a dominate market position in physician offices for these products and a growing market share in surgery centers and hospitals.

Battery Operated Cauteries - Approximate worldwide market $10 million
Battery operated cauteries represent the Company's original line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The Company estimates it manufactures more types of cauteries than any other company in the world controlling up to 70% of the market, including a line of replaceable battery and tip cauteries, which are popular in overseas markets.
 

.
 This corporate information sheet is intended to provide general information about the Company. It is not designed to be a source for making investment decisions, and Bovie will make every reasonable effort to include accurate and current information. Except for the historical information contained herein, this information may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company's SEC filings. Neither Bovie Medical Corporation nor any party involved in creating, producing or delivering this information sheet shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user's access, use, or liability to use the corporate information sheet, or any errors or omissions in the content.